ClinicalTrials.gg
RecruitingNCT05885295IC3Updated Jun 1, 2023

The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)

An observational study in Stroke, Stroke (CVA) or TIA and Dementia, Vascular, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-01.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Stroke by Imperial College London — 2 open to participants now, 2 under way, none of them phase 3. Stroke · Imperial College London.

Started
2021
with 2 others
Observational
5 of 19
1 open now
Registered
18th of 19
by date

Among the 19 studies in Stroke by Imperial College London, this one is one of 3 that started in 2021, is one of 5 observational ones, and was the 18th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

2 of the 19 studies in Stroke by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Stroke by Imperial College London, or all of them as a file.
02

Study summary

Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors. These deficits negatively impact recovery and therapy engagement, and their treatment is consistently rated as high priority by stakeholders and clinicians. Although clinical guidelines endorse cognitive screening for post-stroke management, there is currently no gold standard approach for identifying cognitive deficits after stroke, and clinical stroke services lack the capacity for long-term cognitive monitoring and care. Currently available assessment tools are either not stroke-specific, not in-depth or lack scalability, leading to heterogeneity in patient assessments. To address these challenges, a cost-effective, scalable, and comprehensive screening tool is needed to provide a stroke-specific assessment of cognition. The current study presents such a novel digital tool, the Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3), designed to detect both domain-general and domain-specific cognitive deficits in patients after stroke with minimal input from a health professional. To ensure its reliability, we will utilise multiple validation approaches, and aim to recruit a large normative sample of age-, gender-, and education-matched UK-based controls. Moreover, the IC3 assessment will be integrated within a larger prospective observational longitudinal clinical trial, where post-stroke cognition will be examined in tandem with brain imaging and blood biomarkers to identify novel multimodal biomarkers of recovery after stroke. By leveraging this rich dataset, our study will allow more precise targeting of cognitive rehabilitation to stroke survivors that are most at risk of progressive cognitive decline and have the greatest potential for recovery.

Read the detailed description

Aims and objectives

  1. Develop an adaptive, scalable, self-administered, digital comprehensive cognitive screening tool to detect cognitive impairments in patients with cerebrovascular disease. The IC3 will:

    I. Detect both domain-general (e.g. executive function) and domain-specific (e.g. aphasia, apraxia, neglect) deficits post-stroke.

    II. Allow monitoring to occur at scale, in a cost-efficient manner, as test administration can occur independent of trained professionals.

    III. Minimise the effects of neglect or aphasia on cognitive assessments. IV. Have high test-re-test reliability for repeated-testing longitudinally.

  2. Validate the IC3 against commonly used cognitive screening tools.
  3. Apply the IC3 in a cohort of stroke survivors, as part of the main study, to map their trajectory of cognitive impairment over the course of the first year after stroke.
  4. Identify novel biomarkers of cognitive outcome (cognitive scores at 1 year) and recovery trajectory through the main study using:

I. Premorbid demographics, and comorbid physical, neuropsychological and socioeconomic factors II. Structural and functional MRI brain imaging, to assess metrics of cerebrovascular disease load, stroke lesion topology and brain network dynamics.

III. Blood biomarkers of neurodegeneration (total microtubule-associated protein TAU; Phosphorylated TAU isoforms; Amyloid Aβ42/40 ratio) and neuroaxonal injury (Neurofilament Light - NFL; Glial Fibrillary Acidic protein - GFAP). The study will characterise the time course of the blood biomarkers over the first year after acute stroke and relate these to MRI measures of axonal injury and brain atrophy, as well as cognitive and functional outcomes at 12 months.

IC3 Assessment Design and Development

Cognitive tests. The IC3 assessment covers 22 short tasks, spanning a wide range of cognitive domains followed by several clinically-validated questionnaires, designed to be completed in under 60-70 minutes. IC3 is available via a web-browser on any modern device (smartphone, tablet, computer/laptop). To launch the assessment, the participant clicks on a link created by the study team.

The digital nature of the IC3 affords scalability in cognitive monitoring by being usable in both the clinical setting and home environment in the absence of a trained clinician. As well as reducing healthcare costs, this feature promotes accessibility of the assessment for physically disabled patients in whom attendance to healthcare or research setting is difficult. Compared to pen and paper tests, the IC3 test administration is standardised, scoring is automated and more detailed response metrics per individual tests are collected (e.g. capturing reaction time and trial-by-trial variability in responses, as well as accuracy). This allows real-time evaluation of cognitive impairments against normative samples of age-, education- and sex- matched controls.

Demographic and neuropsychiatric questionnaires. A number of health questionnaires and modified versions of relevant clinically-validated questionnaires are completed by the patient or carers to assess mood, apathy, fatigue and sleep.

At the end of the assessment the participant will be given a graphical, easy-to-understand diagram that highlights their performance against normative data. The normative data will be based on single time-point data collected remotely from large sample of healthy controls (>3000).

Main IC3 study design

This prospective observational longitudinal study aims to recruit 300 patients with acute stroke and obtain repeated measures of cognition and psychosocial status at baseline, 3-months, 6-months and 12-months post ictus. IC3 is currently a single-site study at Imperial College Healthcare NHS Trust, England, and commenced recruitment in 2022. In addition to the cognitive monitoring, all patients will be invited to take part in MRI brain imaging and blood biomarker sub-studies.

IC3 validation sub-study. A minimum of 100 patients will undergo clinically validated pen and paper cognitive screens. Test-retest reliability analyses will estimate the impact of learning effects on performance, and compare remote administration with in-person delivery of the assessment.

MRI sub-study. Clinically acquired brain imaging at the time of the acute stroke (including FLAIR and DWI sequences) will be obtained. All 300 patients will be invited to undergo additional brain MRI imaging at 3 and 12 months using a Siemens Verio 3T scanner at the Imperial College Clinical Imaging Facility. MRI measures will be used as prognostic indicators for cognitive trajectory.

Blood biomarkers sub-study. Blood samples will be obtained at baseline, and at 3, 6 and 12 months from 200 patients. Two EDTA (plasma) and two SST (serum) samples will be collected. Sample processing involves centrifugation at 2000g for 10 minutes at 4°C, followed by secure storage at -80°C. Additional single PAXgene sample will be collected at one time point for DNA storage for future analysis. The primary plasma biomarker of interest will be NFL. Additional markers including GFAP, total TAU, phosphorylated TAU and Amyloid Aβ42/40 ratio will be quantified. Testing will be performed at University College London via a digital ELISA technique, using a Quanterix Simoa analyser to provide ultrasensitive assessment of concentrations.

Study Population

Participant identification, recruitment and consent. Patients will be recruited from the Imperial College Healthcare NHS Trust by study personnel and the clinical team. Our goal is to recruit patients as early after stroke as is practical, and ideally within ten days to facilitate acute blood biomarker assessment. Those satisfying the inclusion and exclusion criteria will be approached and consented. If a patient is unable to provide fully informed consent, for example due to severe aphasia, we will assent with permission from a consultee. Patients that have been assented will be reconsented if they are subsequently able to provide full informed consent. The consent procedure will be carried out in strict compliance with national legislation and General Data Protection Regulation. Control participants will be aged > 18 and without history of neurological illness or serious psychiatric illness.

03

Conditions studied

  • Stroke
  • Stroke (CVA) or TIA
  • Dementia, Vascular
  • Cerebrovascular Disorders
  • Small Vessel Cerebrovascular Disease
  • Cognitive Impairment

Keywords

  • dementia
  • MRI
  • blood biomarkers
  • neurofilament light
  • amyloid
  • tau
  • GFAP
  • white matter hyper intensity
  • micro bleed
  • small vessel disease
  • cognitive impairment
  • vascular dementia
  • stroke
  • aphasia
  • neglect
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients with stroke

Eligibility criteria

Inclusion Criteria:

  • Aged > 18
  • Evidence of confirmed stroke (for patients)
  • Ability to concentrate for 15 minutes at a time to engage with cognitive testing

Exclusion Criteria for the main study:

  • Pre-stroke diagnosis of dementia
  • Severe visuo-spatial problems, fatigue, or mental health problems
  • Severe hearing impairment in the presence of reading comprehension impairment

Exclusion Criteria for the MRI imaging sub-study:

  • Pregnancy
  • Presence of metal implants
  • Claustrophobia
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patient

    Patient with stroke

    Diagnostic Test: MRI brain, Blood tests, cognitive assessments

  • Controls

    Age-matched controls

    Diagnostic Test: MRI brain, Blood tests, cognitive assessments

Interventions

  • Diagnostic testMRI brain, Blood tests, cognitive assessments

    observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests

06

What researchers measure

Primary outcomes

  1. cognition

    IC3-derived accuracy measures on cognitive testing Scale title: The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease Impairment value defined as \<1.5 Standard Deviation Units below the age and education -matched control sample Lower values mean worse outcome

    Time frame: 1 year after stroke

Secondary outcomes

  1. MOCA

    Clinically derived MOCA scores for cognition Scale title: The Montreal Cognitive Assessment Range 0-30. Lower values mean worse outcome.

    Time frame: 1 year post stroke

  2. NIHSS

    NIH Stroke Scale Scale title: National Institute of Health Stroke Scale Range: 0-24 Lower values mean better outcome.

    Time frame: 1 year post stroke

  3. Lawton and Brody Instrumental activities of daily living (IADL)

    Scale title: Lawton and Brody Instrumental Activities of Daily Living Source: Lawton, M.P., and Brody, E.M. "Assessment living." Gerontologist 9:179-186, (1969). Range: 0-8 Lower values mean worse outcome.

    Time frame: 1 year post stroke

  4. MRS

    Scale title: Modified Rankin Scale Range: 0-6 Lower values mean better outcome.

    Time frame: 1 year post stroke

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Anonymised data used in publications may be shared on reasonable request from PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for May 2028, 77 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 77 months is above that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
Jun 1, 2023
StartActual
Dec 1, 2021
Primary completionEst.
May 15, 2028
CompletionEst.
May 15, 2028
Last update
Jun 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05885295
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Dec 1, 2021
Primary completion
May 15, 2028 (estimated)
Completion
May 15, 2028 (estimated)
Last update
Jun 1, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion